STX-140
STX-140 is a small molecule drug that is currently under investigation for its potential use in the treatment of cancer. It is a derivative of the natural product 2-methoxyestradiol (2ME2), which has been shown to have anti-cancer properties. STX-140 is being developed by Sterix Ltd, a subsidiary of Ipsen.
Mechanism of Action[edit | edit source]
STX-140 works by inhibiting microtubule formation, a crucial process in cell division. By preventing the formation of these structures, STX-140 effectively halts the division and growth of cancer cells. In addition to this, STX-140 has been shown to induce apoptosis, or programmed cell death, in cancer cells.
Clinical Trials[edit | edit source]
STX-140 has undergone several phases of clinical trials. Early phase trials demonstrated the drug's safety and potential efficacy in treating various types of cancer. Currently, STX-140 is in Phase II clinical trials where it is being tested for its effectiveness in treating breast cancer and prostate cancer.
Potential Applications[edit | edit source]
If successful in clinical trials, STX-140 could be used as a treatment for a variety of cancers. Its mechanism of action suggests that it could be particularly effective in treating cancers that are resistant to other forms of treatment.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
